| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
4-Hydroxyantipyrine does not have a direct pharmacological target. It is a metabolite of antipyrine and serves as a biomarker for CYP3A4 enzyme activity. The compound's formation from antipyrine is catalyzed by CYP3A4, a major drug-metabolizing enzyme in the liver. As a biodistribution promoter, it may affect the distribution of other compounds in the body. However, it is not a drug itself and does not have a defined therapeutic mechanism of action. It is used in research as a tool to study drug metabolism and enzyme activity.
|
|---|---|
| ln Vitro |
4-Hydroxyantipyrine raises the ratios of thiopental to tissue-to-plasma concentration in the heart, liver, and brain as well as the ratio of citicoline to tissue-to-plasma concentration in the liver and brain [1]. 4-hydroxyantipyrine can improve the permeability of antipyrine across the blood-brain barrier (BBB), which makes sense given that it is linked to an increase in antipyrine Kp value in the brain [2].
In vitro, 4-Hydroxyantipyrine is used as a standard in analytical chemistry for the quantification of antipyrine metabolism. It is detected and quantified using LC-MS/MS or HPLC methods. The compound's formation kinetics (Vmax = 1.54 nmol·mg⁻¹·min⁻¹) have been validated, making it a reliable marker for CYP3A4 activity. It is not a pharmacologically active compound in cell-based assays but is used as a reference standard. Its role as a biodistribution promoter may be studied in cell-based models of drug transport. |
| ln Vivo |
In vivo, 4-Hydroxyantipyrine is the major urinary metabolite of antipyrine. It is formed by CYP3A4-dependent metabolism and excreted in the urine. The compound is used as a probe to assess CYP3A4 activity in vivo by measuring the urinary excretion of 4-hydroxyantipyrine following antipyrine administration. It may also act as a biodistribution promoter, increasing the brain concentration ratio of other compounds. However, it is not administered as a therapeutic agent.
|
| Enzyme Assay |
In vitro assays for 4-Hydroxyantipyrine are primarily analytical. LC-MS/MS and HPLC methods are used to quantify the compound in biological samples such as urine and plasma. These methods are validated for sensitivity and specificity. The compound is used as a standard for method development and validation. No enzyme or receptor binding assays are applicable, as the compound is a metabolite and not a drug targeting a receptor.
|
| Cell Assay |
Cell-based assays for 4-Hydroxyantipyrine are not typically performed, as the compound is a metabolite and not a pharmacologically active agent. It may be used in cell-based models of drug metabolism to study CYP3A4 activity. Cells expressing CYP3A4 can be incubated with antipyrine, and the production of 4-hydroxyantipyrine can be measured. However, the compound itself is not used as a treatment in cell culture.
|
| Animal Protocol |
In vivo animal experiments with 4-Hydroxyantipyrine are not applicable, as the compound is not a therapeutic agent. However, animal models are used to study antipyrine metabolism and CYP3A4 activity. Antipyrine is administered to animals, and the urinary excretion of 4-hydroxyantipyrine is measured. These studies are used to assess the effects of other drugs or disease states on CYP3A4 activity. The compound itself is not administered.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
4-Hydroxyantipyrine is a known human metabolite of antipyrine. Pharmacokinetic properties of 4-Hydroxyantipyrine are characterized by its formation and elimination as a metabolite of antipyrine. It is formed in the liver by CYP3A4 and excreted in the urine. The compound has a molecular formula of C11H12N2O2 and a molecular weight of 204.23. It is a white to off-white solid. Solubility: soluble in DMSO and ethanol. Storage: room temperature, protected from light. |
| Toxicity/Toxicokinetics |
Safety and toxicology data for 4-Hydroxyantipyrine are limited. As a metabolite of antipyrine, it is generally considered safe at the concentrations found in the body following therapeutic doses of antipyrine. The compound is for research use only and is not for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. No specific toxicity data are available.
|
| References | |
| Additional Infomation |
4-Hydroxy-1,5-dimethyl-2-phenyl-3-pyrazolone is a cyclic compound belonging to the pyrazolium class of compounds.
4-Hydroxyantipyrine has CAS number 1672-63-5, molecular formula C11H12N2O2, and molecular weight 204.23. It is the primary metabolite of antipyrine and accounts for approximately 21.8% of the administered dose. Its formation is CYP3A4-dependent. It is used as a biomarker in pharmacokinetic and drug metabolism studies. It can act as a biodistribution promoter. Purity: typically ≥98%. Not for human use; for research purposes only. |
| Molecular Formula |
C11H12N2O2
|
|---|---|
| Molecular Weight |
204.2252
|
| Exact Mass |
204.09
|
| CAS # |
1672-63-5
|
| Related CAS # |
4-Hydroxyantipyrine-d3;65566-65-6
|
| PubChem CID |
98889
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.294g/cm3
|
| Boiling Point |
314.3ºC at 760mmHg
|
| Melting Point |
184-186ºC(lit.)
|
| Flash Point |
143.9ºC
|
| Vapour Pressure |
0.000199mmHg at 25°C
|
| Index of Refraction |
1.63
|
| LogP |
1.19
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
15
|
| Complexity |
306
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SKVPTPMWXJSBTF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H12N2O2/c1-8-10(14)11(15)13(12(8)2)9-6-4-3-5-7-9/h3-7,14H,1-2H3
|
| Chemical Name |
4-hydroxy-1,5-dimethyl-2-phenylpyrazol-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~244.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8964 mL | 24.4822 mL | 48.9644 mL | |
| 5 mM | 0.9793 mL | 4.8964 mL | 9.7929 mL | |
| 10 mM | 0.4896 mL | 2.4482 mL | 4.8964 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
